Quintiles Library

Harnessing Vital Data Image
Featured White Paper

Harnessing vital data to inform an optimal market access strategy in the UK
Market access now demands closer collaboration between biopharma, payers and providers. In a climate where ongoing reimbursement of a drug relies on biopharma’s ability to demonstrate how it delivers value to the entire healthcare system, partnership working is essential. Outcomes audits should be seen as one of the most important tools available to biopharma. They deliver detailed action plans to both biopharma and the NHS, proposing improvements to the care pathway...


















































































Remove allSelected Topics:
    White Paper
    In the past, when smaller U.S. biopharmaceutical companies wanted to enter the European market, they had two choices – go it alone, an approach that includes substantial cost, risk and uncertainty; or out-license the product to another company, which required them to give up control of the product and perhaps lessen the long-term value of their portfolio. Now they have a third option. By partnering with a well-established outsourcing specialist they can overcome much of the risk while taking advantage of a vast network of human resources and infrastructure across Europe. Through these partnerships, smaller biopharma companies can more efficiently get their drug into the market – without giving up strategic control or long-term value.  This paper outlines the challenges North American...
    Explore More
    Fact Sheet
    The market access challenge requires a successful response to multiple stakeholders from different countries – each with their own needs and requirements. Anticipating these diverse demands and developing the necessary evidence requires a nuanced understanding of the dynamic payer environments you must navigate. Quintiles’ HTA Accelerator offers an integrated solution providing payer insights for launch...
    Read More
    Fact Sheet
    Healthcare systems across Asia Pacific are evolving - as expenses rise alongside improvements in care, payers are increasingly demanding proof of value from new medicines. For today’s drug developers, the emphasis has shifted from “time to market” to “time to access.” By clearly communicating a strategic and cohesive value message to key stakeholders, the path to market access can be navigated more effectively and efficiently. Discover how Medical Science Liaisons (MSLs) can be an integral part of your team and gain a deeper insight into: The difference between a traditional sales representative and a MSL How MSLs can help to prepare the market during the pre-launch phase Effectively engaging with key opinion leaders (KOLs) and stakeholders Best practice and key success...
    Read More
    Fact Sheet
    Getting a clinical trial off to the right start is vital. However, across the industry, trials face multiple delays and 20% of sites recruit zero patients, due to the scarcity of good information. An optimized approach to start-up that leverages data, analytics, process expertise and site relationships has enabled faster start-up. See how Quintiles’ can establish a solid route to trial execution...
    Read More
    Press Release
    RESEARCH TRIANGLE PARK, NC – October 14, 2014 – Quintiles today announced that the company was awarded the Society for Clinical Research Sites’ (SCRS) 2014 Clinical Research Organization (CRO) Eagle Award. The award, which recognizes outstanding leadership, professionalism, integrity, passion and dedication, was presented during the annual SCRS Site Solutions Summit. "It is such an honor to be recognized again and receive this award for the second year in a row,” said Lindy Jones, senior vice president, Integrated Site Services, Quintiles. “Our ambition of transforming clinical development and accelerating pipelines to achieve better patient outcomes is only possible through the dedication and hard work of our investigators and sites. I would like to thank the investigators who voted for...
    Read More
    White Paper
    How is next generation sequencing (NGS) transforming oncology clinical development and treatments for cancer?  Read this recent whitepaper to learn how.  The overall goal in the era of emerging precision is to develop cancer medications that attack the right target, or targets, in the right disease, in the right patient, at the right dose to obtain the desired outcome.  Several targeted therapies have successfully been developed and the pipeline of additional precision medicines looks promising.  But how can the drug development community better capitalize on sophisticated genomics-based tools available to help transform clinical development and cancer care in the coming decade? This paper investigates fundamentals and key considerations to integrating NGS in the clinical development of...
    Explore More
    Presentation
    Biopharma’s success in the new healthcare economy is predicated on one simple principle: prove the value of your treatments or risk losing market share and profits. Healthcare costs are climbing, regulators around the globe are requiring more information, and both providers and payers have higher expectations for a medical treatment’s proof of value before prescribing or paying for those treatments. These quality, cost and outcome driven imperatives must also incorporate efficacy, safety, benefits as compared with competing products, and overall improved quality of life.  Download the presentation given by Paul Sutton, Director of Outcomes at Quintiles Commercial UK, entitled: “Value is the target: aligning value for payers to pharma”.  Paul Sutton leads the design and implementation of...
    Explore More
    Presentation
    Biopharma's success in the new healthcare economy is focused on a clear guiding principle: prove the value of the product to all stakeholders, or risk commercial failure. In the UK, the number of budget holders has vastly increased, with NICE, NHS England, the Cancer Drug Fund and the proliferation of clinical commissioning groups all now demanding drugs that deliver exceptional value. 'UK payers perspectives: the market access value paradox' features Ryan Wooller, Director of Market Access and Service Innovation at Quintiles and Dr Junaid Bajwa, a GP and board member for Greenwich CCG. The webinar will examine exactly why there is a misalignment between biopharma and payers, how it is harming the commercial and clinical success of products, and what needs to be done to bring them closer...
    Explore More
    Media Coverage
    An overview of benefit-risk management in the lifecycle of medical procedures and the effect of recent EU legislation (in German) from PM Report. Link to Christoph’s blog on Quintiles.com - http://www.quintiles.com/experts/christoph-schnorr Bekommen Sie einen Überblick über Benefit-Risk Management im Lebenszyklus von medizinischen Verfahren und die Auswirkungen der letzten Gesetzesänderungen auf EU Ebene - PM Report. Link zu Christoph’s blog on Quintiles.com -...
    Read More
    Fact Sheet
    When it comes to central lab performance, you expect speed and accuracy. And that’s what you’ll get through online access to Quintiles Infosario® Analytics and Infosario Site Gateway, connected to all of your trials run through Quintiles Central Labs.   Learn how Quintiles’ Infosario technology platform enables study sponsors to see trial lab data at a deeper level to improve the quality of their...
    Read More
    Brochure
    With new technologies and partnerships opening up unprecedented access to patient data, generating evidence that can demonstrate the effectiveness and safety of your products under real-world conditions is more important than ever. Many healthcare stakeholders, including physicians, payers and regulators, are all seeking real-world outcomes to determine what works best for different patient subgroups in different situations. Observational research and patient registries can deliver this type of evidence to meet your stakeholders’...
    Read More
    Media Coverage
    Since its founding in 1982, Quintiles has become a leading clinical research organization, from first-in-human studies to post-launch monitoring. In 2013, Quintiles acquired Expression Analysis (EA) to expand its genomic testing analysis services throughout the entire process of drug discovery and development. Dr. Patrick Hurban, a trained molecular biologist and geneticist and EA’s Global Head of Genomic R&D, tells Nature how the marriage between EA and Quintiles benefits...
    Read More
    Press Release
    RESEARCH TRIANGLE PARK, N.C. – September 30, 2014 – Quintiles Transnational Holdings Inc. (NYSE: Q) will release its third-quarter 2014 financial results Thursday, October 30, 2014 prior to its quarterly earnings call at 8:00 a.m. EDT. The conference call will be accessible, live via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com/investors. To participate via telephone, please dial +1 (855) 484-7367 in the United States or +1 (631) 259-7541 outside the United States, approximately 15 minutes before the scheduled start of the call. An archived edition of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EDT on Thursday, October 30th. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the...
    Read More
    Fact Sheet
    Despite major medical advances in the fields of allergy and respiratory medicine, there is still no definitive cure for chronic conditions such as asthma, COPD, IPF, and CF. And with research in these indications being one of the most intensely competitive areas in drug development, sponsors have only increasing pressures to deliver more effective treatments through their clinical development programs. Quintiles Allergy and Respiratory (ART) Center of Excellence can help advance your studies in these and related indications from early clinical development to post-marketing studies. With pulmonologists, respiratory medical and senior advisors, and experienced operational staff across the globe, we will help: integrate the scientific, therapeutic, operational, and commercial components...
    Read More
    Media Coverage
    On Friday, September 19, The Maeil Business Newspaper, South Korea’s leading daily financial and business publication, published a “View and Outlook” interview with Quintiles CEO Tom Pike about outsourcing as a business strategy and Quintiles’ capabilities to help biopharma companies improve their probability of success. "A business can focus on its core competence while maintaining its competitiveness in other secondary areas by employing an outsourcing strategy. Outsourcing contracts with firms equipped with advanced technology and credibility generates great synergistic effect on the overall business," said Tom Pike, CEO of Quintiles, in the interview with Maeil Business Review MBA team. Below is the Q&A with Mr. Pike. Click on the download button above to view the original article...
    Read More
    Fact Sheet
    Whether your company holds one or multiple product authorizations, a fit-for purpose, clear and transparent signal detection strategy is core to the success of your pharmacovigilance program. Every product’s signal strategy must be adapted to address its safety profile, stage in the lifecycle, and must align with a well-defined risk-based signal management process to ensure proper signal prioritization, escalation and time-sensitive decision making No matter if you want to outsource just one or all steps of your signal management process, our in-house team of experts can help you devise a holistic strategy. Find out more when you download this fact...
    Read More
    Video
    Dr. Dennis Gillings, CBE, World Dementia Envoy, discusses the global burden of Alzheimer’s disease and how the G7 is driving new public-private efforts to drive new research into innovative prevention and therapy approaches to the disease. This is the player to use for single videos on Q.com ...